Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel full. When the drug interacts with a receptor in the stomach, patients feel full sooner and for a longer period of time after eating. The drug does not cause weight loss directly – instead, it makes you want to eat less.

Sima Sistani helped push the company into the GLP-1 drug space with the $106 million acquisition of Sequence.